Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on AbbVie (ABBV) to $207 from $205 and keeps an Outperform rating on the shares. AbbVie showed strong confidence in their neuro franchise, with positive sentiment around early-stage business development, while the reported, potential Gilgamesh acquisition could be “a boon for the psychedelics sector, with positive regulatory signals and strong data translating across mechanisms of action,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $236 from $227 at Raymond James
- AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
- AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
- AbbVie Reports Strong Q2 2025 Financial Results
- M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics